Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EVER Pharma gains EU Marketing Authorization for Trabectedin
Details : EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.
Product Name : Trabectedin EVER Pharma
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2024
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SON-1010,Trabectedin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial with Trabectedin in Sarcomas
Details : SON-1010 (IL12-FHAB) is a immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : SON-1010,Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxorubicin Hydrochloride,Trabectedin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : PharmaMar | Ligue contre le cancer | National Research Agency, France | University Hospital Marseille | Institut Claudius Regaud | Institut Bergonié | Oncopole
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
July 29, 2024
Lead Product(s) : Doxorubicin Hydrochloride,Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : PharmaMar | Ligue contre le cancer | National Research Agency, France | University Hospital Marseille | Institut Claudius Regaud | Institut Bergonié | Oncopole
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmamar Receives US$10 Million Milestone Payment from Janssen
Details : Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Product Name : Yondelis
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 11, 2023
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Valeo Pharma Commences Yondelis® Commercialization in Canada
Details : Yondelis (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, that acts a DNA inhibitor. It is indicated for the treatment of of patients with unresectable or metastatic liposarcoma or leiomyo...
Product Name : Yondelis
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 11, 2023
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Global Sarcoma Therapy Now Approved for New Zealand Patients
Details : Yondelis (trabectedin) binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix triggering a cascade of events like DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell d...
Product Name : Yondelis
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2023
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmamar Receives US$10 Million Milestone Payment from Janssen
Details : Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Product Name : Yondelis
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 12, 2022
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Trabectedin,Ttf-Ngr
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Anturec Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
tTF-NGR Randomized Study - STS
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2022
Lead Product(s) : Trabectedin,Ttf-Ngr
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Anturec Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Natco Pharma Gets Tentative Approval for Yondelis Generic
Details : Yondelis-Generic (trabectedin) is a DNA inhibitor, small molecule drug candidate. It is being developed for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
Product Name : Yondelis-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2022
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GLOBAL Sarcoma Therapy Now Approved for Australian Patients
Details : The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-con...
Product Name : Yondelis
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : Trabectedin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable